An FDA approval now looks all but certain for Eisai and Biogen's lecanemab. But before lecanemab can clear the name of the amyloid beta theory after the fallout from Biogen's Aduhelm launch and before the drug can realize its megablockbuster sales potential down the road, there’s one major hurdle to cross—reimbursement.
No comments:
Post a Comment